Dr. Mitch Jones is an accomplished physician and executive with extensive experience in the development of innovative therapeutics for inflammatory and fibrotic diseases. As Chief Medical Officer at Palisade Bio, Dr. Jones oversees all clinical development programs, regulatory strategies, and medical affairs, ensuring the advancement of the company’s pipeline in inflammatory, autoimmune and fibrotic disease.
Dr. Jones has a distinguished track record of advancing innovative therapies from translational research through clinical development and achieving regulatory approvals. He most recently served as Vice President of Corporate Development & Strategy at Chemomab Therapeutics, where he directed corporate strategy, program development, and strategic partnerships. His efforts were instrumental in advancing Chemomab’s clinical-stage programs and supporting the company’s financing and M&A activities.
Prior to Chemomab, Dr. Jones held key leadership roles at Finch Therapeutics and Biora Therapeutics (formerly Progenity). At Finch Therapeutics, he was Vice President of Clinical Discovery and Development, contributing to the company’s IPO and the early clinical development of novel therapeutics for IBD, chronic hepatitis B, and solid tumor immunotherapy. At Biora Therapeutics, he served as Vice President of Innovation and Clinical Translational Development, where he lead the development of the company’s technology platforms including Navicap™ and Biojet™, executed early clinical development and proof of efficacy studies, created strategic roadmaps and played a pivotal role in securing $125 million in venture financing and leading the company through its IPO. His early role within the company was building the GI therapeutics division as Vice President of Translational and Clinical Development.
Dr. Jones founded Interface Therapeutics, where he developed a novel sampling platform for multi-omics analysis of GI tract samples, leading to the discovery of locally acting therapeutics for IBD. Interface Therapeutics was later acquired by Biora Therapeutics. Earlier in his career, he founded Micropharma, where he developed the FDA-approved product LRC™, now sold globally by Chr. Hansen, and achieved regulatory approvals for microbiome-based therapeutics for metabolic and inflammatory diseases.
Dr. Jones is an inventor on nearly 200 patents and has authored numerous scientific publications. He holds MD and PhD degrees.
What is Mitchell Lawrence Jones' net worth?
The estimated net worth of Mitchell Lawrence Jones is at least $182.38 thousand as of July 7th, 2026. Dr. Jones owns 94,009 shares of Palisade Bio stock worth more than $182,377 as of August 3rd. This net worth evaluation does not reflect any other investments that Dr. Jones may own. Learn More about Mitchell Lawrence Jones' net worth.
How do I contact Mitchell Lawrence Jones?
Has Mitchell Lawrence Jones been buying or selling shares of Palisade Bio?
During the past quarter, Mitchell Lawrence Jones has sold $106,354.00 in shares of Palisade Bio stock. Most recently, Mitchell Lawrence Jones sold 51,880 shares of the business's stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $2.05, for a transaction totalling $106,354.00. Following the completion of the sale, the insider now directly owns 94,009 shares of the company's stock, valued at $192,718.45. Learn More on Mitchell Lawrence Jones' trading history.
Who are Palisade Bio's active insiders?
Are insiders buying or selling shares of Palisade Bio?
During the last year, Palisade Bio insiders bought shares 6 times. They purchased a total of 125,000 shares worth more than $250,100.00. During the last year, insiders at the sold shares 4 times. They sold a total of 204,563 shares worth more than $420,524.61. The most recent insider tranaction occured on July, 9th when Director Robert Jr. Baltera bought 25,000 shares worth more than $49,000.00. Insiders at Palisade Bio own 0.1% of the company.
Learn More about insider trades at Palisade Bio. Information on this page was last updated on 7/9/2026.
